Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review

Abstract

Parkinson’s disease (PD) is a common neurodegenerative disorder that leads to significant morbidity and disability. PD is caused by a loss of dopaminergic, cholinergic, serotonergic, and noradrenergic neurons in the central nervous system (CNS), and peripherally; the syndromic parkinsonism symptoms of movement disorder, gait disorder, rigidity and tremor are mostly driven by the loss of these neurons in the basal ganglia. Unfortunately, a significant proportion of patients taking levodopa, the standard of care treatment for PD, will begin to experience a decrease in effectiveness at varying times. These periods, referred to as “off episodes”, are characterized by increased symptoms and have a detrimental effect on quality of life and disability. Istradefylline, a novel adenosine A2A receptor antagonist, is indicated as a treatment addition to levodopa/carbidopa in patients experiencing “off episodes”. It promotes dopaminergic activity by antagonizing adenosine in the basal ganglia. This review will discuss istradefylline as a treatment for PD patients with off episodes.

Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia

“…Adora2a, encoding for Adenosine A 2A receptor (A 2A R) is a G-protein coupled receptor that regulates the balance of adenosine/dopamine signalling through its interactions with D 2 R [ 95 – 97 ]. Adenosine decreases dopamine signalling through D 2 R, while A 2A R antagonists, such as caffeine are believed to enhance dopamine signalling through D 2 R [ 96 , 98 , 99 ]. Our RNAseq analysis revealed a downregulation of striatal and PFC Adora2a expression in Gdnf cHyper ;Nestin-Cre mice (Figs.…”

The Good, the Bad, and the Deadly: Adenosinergic Mechanisms Underlying Sudden Unexpected Death in Epilepsy

“…A 1 receptor knockout mice are more vulnerable to hypoxic/ischemic damage (Johansson et al, 2001), whereas the converse is true in A 2A receptor knockout mice (Chen et al, 1999). A 2A receptor antagonists alleviate hypoxic/ischemic damage in vivo (Gao and Phillis, 1994;Phillis, 1995;Von Lubitz et al, 1995) and the A 2A receptor antagonist KW-6002 is now FDA approved as an adjunct treatment for Parkinson's disease (Berger et al, 2020;Chen and Cunha, 2020). The Good: Adenosine increases seizure threshold, is critical for seizure termination, and may alleviate some of the adverse effects of seizures.…”

Update on Parkinson's Disease Therapy

“…These trials were evaluated by the FDA in 2008, which did not approve its use due to concern that the motor improvement shown in the trials was too small and not clinically significant. Further trials were then conducted, 22 and based on the newer data, the FDA did approve its use in 2019. [27][28][29] New formulations of levodopa designed to be used as needed…”